Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.

Spackman E, Rice S, Norman G, Suh DC, Eastwood A, Palmer S.

Pharmacoeconomics. 2013 Mar;31(3):185-94. doi: 10.1007/s40273-013-0023-z. Review.

PMID:
23371465
2.

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

Whyte S, Pandor A, Stevenson M.

Pharmacoeconomics. 2012 Dec 1;30(12):1119-32. doi: 10.2165/11597210-000000000-00000. Review.

PMID:
23058097
3.

Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.

Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, Marshall E, Plummer R, Proudlove C.

Pharmacoeconomics. 2013 Dec;31(12):1121-9. doi: 10.1007/s40273-013-0094-x. Review.

PMID:
24114739
4.

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.

Rafia R, Simpson E, Stevenson M, Papaioannou D.

Pharmacoeconomics. 2013 Jun;31(6):471-8. doi: 10.1007/s40273-013-0044-7. Review.

PMID:
23568332
5.

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.

McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2012 Jan;30(1):35-46. doi: 10.2165/11594280-000000000-00000. Review.

PMID:
22136303
6.

Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.

Ward S, Pilgrim H, Hind D.

Health Technol Assess. 2009 Jun;13 Suppl 1:1-6. doi: 10.3310/hta13suppl1/01.

7.

Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:33-42. doi: 10.3310/hta15suppl1/04. Review.

8.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
9.

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.

Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M.

Pharmacoeconomics. 2010;28(5):351-62. doi: 10.2165/11532160-000000000-00000. Review.

PMID:
20131924
10.

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, Hockenhull J, Martin Saborido C, Oyee J, Ramani VS.

Pharmacoeconomics. 2011 Dec;29(12):1051-62. doi: 10.2165/11591600-000000000-00000.

PMID:
21967156
11.

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.

Fleeman N, Bagust A, Beale S, Dwan K, Dickson R, Proudlove C, Dundar Y.

Pharmacoeconomics. 2015 Jan;33(1):13-23. doi: 10.1007/s40273-014-0206-2. Review.

PMID:
25138171
12.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.

Pharmacoeconomics. 2010;28(6):439-48. doi: 10.2165/11532220-000000000-00000. Review.

PMID:
20465313
13.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
14.

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.

Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, Vale L.

Pharmacoeconomics. 2013 Jan;31(1):15-24. doi: 10.1007/s40273-012-0006-5. Review.

PMID:
23329590
15.

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R.

Pharmacoeconomics. 2011 Nov;29(11):951-61. doi: 10.2165/11589310-000000000-00000. Review.

PMID:
21854080
16.

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.

Boyers D, Jia X, Jenkinson D, Mowatt G.

Pharmacoeconomics. 2012 Jun 1;30(6):483-95. doi: 10.2165/11591550-000000000-00000. Review.

PMID:
22480381
17.

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.

Craig D, Rice S, Paton F, Fox D, Woolacott N.

Pharmacoeconomics. 2013 Feb;31(2):101-10. doi: 10.1007/s40273-012-0018-1. Review.

PMID:
23341194
18.

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.

Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, Dundar Y, Hockenhull J, Proudlove C, Chu P.

Pharmacoeconomics. 2013 May;31(5):403-13. doi: 10.1007/s40273-013-0043-8. Review.

19.

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.

Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JP, Bakhai A.

Pharmacoeconomics. 2013 Apr;31(4):269-75. doi: 10.1007/s40273-013-0036-7. Review.

PMID:
23512147
20.

Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.

Wade R, Rose M, Neilson AR, Stirk L, Rodriguez-Lopez R, Bowen D, Craig D, Woolacott N.

Pharmacoeconomics. 2013 Oct;31(10):841-52. doi: 10.1007/s40273-013-0083-0. Review.

PMID:
23996108
Items per page

Supplemental Content

Write to the Help Desk